LifeMine Therapeutics announced a $263 million funding round to accelerate the clinical development of its lead drug, LIFE-001, aimed at preventing organ transplant rejection. The company’s CEO, Greg Verdine, discussed these developments during a NYSE Live session. This funding boost highlights investor confidence in LifeMine’s innovative biopharmaceutical approach and could impact future transplant treatment options. Meanwhile, the S&P 500 looks to continue gains amid Middle East developments, with new ETF offerings from Goldman Sachs Asset Management also featured in NYSE updates.
Morgan Stanley analyst Bob Huang lowered American International Group's (AIG) price target to $80 from $81, with the stock trading around $76, indicating potential upside. AIG is set to report its Q3 2026 earnings on November 3, with investors focuse...
Vertiv Holdings, a maker of power and cooling equipment for data centers, faces mixed analyst opinions with GLJ Research rating it a "Sell" and BMO Capital giving an "Outperform" rating. Despite a recent stock pullback, the company reported a 241% in...
Apogee Enterprises reported strong fiscal Q2 results with adjusted earnings of $1.17 per share, nearly double the estimated $0.59, and revenue of $391.14 million, surpassing expectations of $362.6 million. This marks a continued trend of beating esti...
McKesson received a bullish price target of $977 from Morgan Stanley, suggesting a 6.7% upside from its current price of $915.45. The company agreed to acquire Option Care Health for $32.05 per share, valuing the deal at approximately $5.8 billion in...
Ameriprise Financial has authorized an additional $5.5 billion for share repurchases through September 2028, supported by $2.1 billion in excess capital and $2.8 billion in liquidity. The company returned $1.9 billion to shareholders in H1 2026, incl...
